利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.041 秒)

    METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY
    1.
    发明申请
    METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY 审中-公开
    用于减少身体损伤后组织损伤的方法和装置

    公开(公告)号：US20090252778A1

    公开(公告)日：2009-10-08

    申请号：US12295879

    申请日：2007-04-05

    申请人： Theodore L. Parker ,  Thai Minh Nguyen ,  John F. Shanley ,  Frank Litvack

    发明人： Theodore L. Parker ,  Thai Minh Nguyen ,  John F. Shanley ,  Frank Litvack

    IPC分类号： A61F2/04 ,  A61K38/28 ,  A61K31/337 ,  A61K31/436 ,  A61K9/00

    CPC分类号： A61K31/337 ,  A61F2/91 ,  A61F2250/003 ,  A61F2250/0068 ,  A61K38/28 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/45

    摘要： Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. The anti-restenotic agents are delivered over an administration period sufficient to reduce the re-narrowing of a blood vessel following a cardiac procedure such as implantation of a device. Preferred anti-restenotic drugs are those that do not reduce the beneficial effects provided by the anti-ischemic drug, such as drugs that do not act on the mammalian target of rapamycin (mTOR).

    摘要翻译： 提供了用于递送治疗剂的方法和装置，其减少由于局部缺血引起的心肌组织损伤和在心脏手术如支架植入之后抑制再狭窄的抗再狭窄剂。 在足以实现心肌组织的缺血或再灌注损伤减少的给药期间将抗缺血剂递送至心肌组织。 抗再狭窄剂在足以减少心脏手术如植入装置后的血管再狭窄的给药期内递送。 优选的抗再狭窄药物是不减少由抗缺血药物提供的有益效果的那些，例如不作用于雷帕霉素哺乳动物靶标（mTOR）的药物。

    Drug Delivery System for Retarding Release of Water Soluble Drugs
    5.
    发明申请
    Drug Delivery System for Retarding Release of Water Soluble Drugs 审中-公开
    用于阻止水溶性药物释放的药物输送系统

    公开(公告)号：US20070172509A1

    公开(公告)日：2007-07-26

    申请号：US11626785

    申请日：2007-01-24

    申请人： Thai Minh Nguyen ,  Theodore L. Parker ,  John F. Shanley

    发明人： Thai Minh Nguyen ,  Theodore L. Parker ,  John F. Shanley

    IPC分类号： A61K31/727 ,  A61K31/65 ,  A61K31/60 ,  A61K31/519 ,  A61K38/28

    CPC分类号： A61K38/28 ,  A61K9/0024 ,  A61K31/519 ,  A61K31/60 ,  A61K31/65 ,  A61K31/727 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/42 ,  A61L2300/43 ,  A61L2300/602 ,  C08L67/04

    摘要： An implantable drug delivery system uses a hydrophobic compound as an outer layer or barrier for retarding release of water soluble drugs from the implantable system. The system includes an inner portion of a water soluble drug in a drug matrix material which stabilizes the drug. An outer portion of the drug delivery system separates the inner portion from a surrounding environment. The outer portion retards the release of the water soluble drug from the inner portion. The outer portion includes a hydrophobic non-polymer compound and a binder. The hydrophobic compound can be another drug which can be delivered at an entirely different release kinetic from the water soluble drug and for treatment of the same or a different condition. When the drug delivery system is implanted in a body the outer portion retards the release of the water soluble drug by controlling fluid passing from the body into the inner portion and by controlling passage of the water soluble drug from the inner portion into the body.

    摘要翻译： 可植入药物递送系统使用疏水性化合物作为外层或屏障来阻止水溶性药物从可植入系统的释放。 该系统包括使药物稳定的药物基质材料中的水溶性药物的内部。 药物递送系统的外部部分将内部部分与周围环境分开。 外部部分阻止水溶性药物从内部的释放。 外部部分包括疏水性非聚合物和粘合剂。 疏水化合物可以是另一种药物，其可以以与水溶性药物完全不同的释放动力学递送并用于治疗相同或不同的病症。 当药物递送系统植入体内时，外部通过控制从身体流入内部的流体并通过控制水溶性药物从内部部分进入体内来阻止水溶性药物的释放。

    Implantable medical device with beneficial agent concentration gradient
    10.
    发明授权
    Implantable medical device with beneficial agent concentration gradient 有权
    具有有益剂浓度梯度的植入式医疗器械

    公开(公告)号：US08449901B2

    公开(公告)日：2013-05-28

    申请号：US11369592

    申请日：2006-03-07

    申请人： John F. Shanley ,  Theodore L. Parker ,  Kinam Park

    发明人： John F. Shanley ,  Theodore L. Parker ,  Kinam Park

    IPC分类号： A61F2/00

    CPC分类号： A61L31/08 ,  A61L31/041 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/60 ,  A61L2300/604

    摘要： The implantable medical devices are configured to release at least one therapeutic agent from a matrix affixed to the implantable body with a release profile which is programmable to the agent and treatment. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the implantable body. The change in the concentration gradient of the agent in the matrix directly controls the rate of elution of the agent from the matrix. The therapeutic agent matrix can be disposed in the stent or on surfaces of the stent in various configurations, including within volumes defined by the stent, such as openings, holes, or concave surfaces, as a reservoir of agent, and alternatively as a coating on all or a portion of the surfaces of the stent structure.

    摘要翻译： 可植入医疗装置被配置为从固定在可植入体上的基质中释放出至少一种治疗剂，其具有可针对药剂和治疗而编程的释放特征。 基质被形成为使得基质中的治疗剂的浓度相对于可植入体的表面的梯度变化。 基质中药剂浓度梯度的变化直接控制药剂从基质中的洗脱速率。 治疗剂基质可以以各种构型设置在支架中或在支架的表面上，包括由支架限定的体积，例如开口，孔或凹面，作为药剂储库，或者作为涂层 支架结构的全部或一部分表面。